TOP TEN perturbations for 39590_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39590_at
Selected probe(set): 209871_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39590_at (209871_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
dengue fever study 10 (DHF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):-4.638734Number of Samples:2 / 5
Experimental | dengue fever study 10 (DHF) |
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis. | |
Control | normal naive CD8 T cell sample |
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):-3.9954357Number of Samples:2 / 3
Experimental | glioma study 16 (LN-229) |
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
T-cell activation study 2 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):-3.9545841Number of Samples:2 / 2
Experimental | T-cell activation study 2 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days.. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):-3.698347Number of Samples:2 / 2
Experimental | T-cell activation study 1 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
stem cell differentiation study 59 (iDRG; 15d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):3.6764765Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 15d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):3.3288364Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 12d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
dengue fever study 10 (DF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):-3.2965565Number of Samples:3 / 5
Experimental | dengue fever study 10 (DF) |
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. | |
Control | normal naive CD8 T cell sample |
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):3.192442Number of Samples:2 / 3
Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
Control | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). |
Langerhans cell histiocytosis study 3 / Langerhans cell histiocytosis study 4
Relative Expression (log2-ratio):-3.1100683Number of Samples:10 / 7
Experimental | Langerhans cell histiocytosis study 3 |
CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease). | |
Control | Langerhans cell histiocytosis study 4 |
CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease). |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):-3.0924969Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal T-cell sample |
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |